In this video health care analysts David Williamson and Max Macaluso discuss Pfizer's just-released third-quarter earnings. David distills the highlights and hits on all of the critical takeaways for investors, including potential blockbuster Eliquis shared with Bristol-Myers Squibb and the "bapi" Alzheimer's failure, which it shares with Elan. Watch and discover everything you need to know about Pfizer's most recent quarter.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.